Medicina cardiovascular

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. Patient-Specific Induced Pluripotent Stem Cell Models for Heritable Channelopathies and Cardiomyopathies

   Rochester, Minn.

   The purpose of this study is to derive and characterize patient-specific disease models for sudden death-predisposing heritable channelopathies and cardiomyopathies using iPS-cell technology.  It is hoped that the molecular, cellular, and electrophysiological phenotypes of these in-vitro disease models will further elucidate the pathophysiologic mechanisms underlying these sudden death-associated conditions.

2. Treating Breast Cancer Patients Undergoing Trastuzumab Treatment with Carvedilol to Reduce Incidence of Heart Failure

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate different strategies of cardiovascular therapy with Carvedilol, aiming to reduce the incidence of left ventricular ejection fraction (LVEF) decline and heart failure (HF) in patients undergoing curative intent Trastuzumab for breast cancer.

    

   .

3. Associated Anomalies with Right and Left Cusp Fusion Versus Right and Non-Coronary Cusp Fusion

   Rochester, Minn.

   The goal of this study is to determine whether significant differences exist in the prevalence of associated cardiac anomalies between right/left and right / non-coronary cusp fusion in bicuspid aortic valve.

4. The "Virtual" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry

   Rochester, Minn.

   The primary goal of this project is to describe the clinical and physiologic characteristics of Spontaneous Coronary Artery Dissections (SCAD) in order to increase awareness, understanding, treatment and prevention of a potentially fatal cardiovascular event.

   This study will be a retrospective and prospective review of medical course and current health of men and women with SCAD.

5. A Study to Develop a Pulmonary Hypertension Association Registry (PHAR)

   Rochester, Minn.

   The primary purpose of this study is to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes).

6. A Study to Evaluate the Safety of Intracoronary Infusion of Extracellular Vesicles in Patients with Acute Myocardial Infarction

   Rochester, Minn.

   The purpose of this study is to determine the acute and long-term dose limiting toxicities of intracoronary infused PEP and the maximum tolerated dose in a cohort of coronary stent implantation patients.

7. A Study of Arrhythmia in Eisenmenger’s Syndrome

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to describe the incidence and type of arrhythmia seen in patients with Eisenmenger syndrome, to define predisposing factors potentially leading to the onset of arrhythmia, and to describe the influence of arrhythmia on outcomes.

8. A Study to Evaluate Potential Myocardial Injury Following Elective Direct Current Cardioversion

   Rochester, Minn.

   The purpose of this study is to prospectively determine if direct current cardioversion (DCCV) results in myocardial injury as assessed by changes in high sensitivity cardiac troponin T (hs-cTnT) assay.

9. International Triadin Knockout Syndrome Registry

   Rochester, Minn.

   The aim of this study is to determine the worldwide prevalence of Triadin Knockout Syndrome (TKOS), and to better define the phenotype of patients with the disease. This information will provide additional insight into which phenotypic markers may be specific to TKOS, and will also help to develop better TKOS specific treatment strategies.

10. Product Surveillance Registry

    Rochester, Minn.

    The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.